Detecting mutations and ploidy in chromosomal segments
The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
1. A method for detecting cancer-specific mutations, comprising:
identify a plurality of cancer-specific mutations from a cancer sample of a subject;
designing PCR primers for amplifying a plurality of target loci encompassing the cancer-specific mutations, wherein the cancer-specific mutations comprise one or more single nucleotide variant (SNV) mutations;
performing a multiplex targeted amplification reaction to amplify the target loci encompassing the cancer-specific mutations using the PCR primers, from cell-free DNA isolated from a biological sample of the subject, to obtain amplicons, wherein the target loci are amplified together in the same reaction volume and not in separate reaction volumes;
performing high-throughput sequencing to sequence the amplicons obtained in the multiplex targeted amplification reaction and determine the sequences of the amplified target loci for the presence or absence of the cancer-specific mutations; and
detecting at least one SNV mutation that is present in less than or equal to 0.015% of cell-free DNA molecules having the SNV locus in the biological sample.
2. The method of claim 1 , wherein the biological sample is a blood, serum, plasma, or urine sample.
3. The method of claim 1 , wherein the subject suffers from lung cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, kidney cancer, melanoma, lymphoma, leukemia, thyroid cancer, liver cancer, pancreatic cancer, gallbladder cancer, gastric cancer, brain cancer, or skin cancer.
4. The method of claim 1 , wherein the cancer-specific mutations are identified by performing whole exome sequencing on the cancer sample.
5. The method of claim 1 , wherein the cancer-specific mutations comprise one or more copy number variation (CNV) mutations.
6. The method of claim 1 , wherein the cancer-specific mutations comprise one or more clonal SNV mutations.
7. The method of claim 1 , wherein the cancer-specific mutations comprise one or more subclonal SNV mutations.
8. The method of claim 1 , wherein the cancer-specific mutations comprise one or more clonal SNV mutations and one or more subclonal SNV mutations.
9. The method of claim 1 , wherein the method further comprises determining clonal heterogeneity of the cancer sample.
10. The method of claim 1 , wherein the method further comprises repeated testing of biological samples obtained from the subject at multiple time points to monitor the progression of cancer or the remission or reoccurrence of cancer.
11. A method for detecting tumor-specific mutations, comprising:
performing whole exome sequencing on tumor biopsy samples obtained from multiple regions of a tumor of a subject to identify a plurality of tumor-specific SNV mutations;
designing PCR primers for amplifying a plurality of target loci encompassing the tumor-specific SNV mutations;
isolating cell-free DNA from a biological sample of the subject;
performing a multiplex targeted amplification reaction to amplify the target loci encompassing the tumor-specific SNV mutations using the PCR primers, from cell-free DNA isolated from a biological sample of the subject, to obtain amplicons, wherein the target loci are amplified together in the same reaction volume and not in separate reaction volumes;
performing high-throughput sequencing to sequence the amplicons obtained in the multiplex targeted amplification reaction and determine the sequences of the amplified target loci for the presence or absence of the tumor-specific SNV mutations, wherein each of the target loci is sequenced with a depth of read of at least 50,000; and
detecting at least one SNV mutation that is present in less than or equal to 0.015% of cell-free DNA molecules having the SNV locus in the biological sample.
12. The method of claim 1 , wherein the multiplex targeted amplification reaction amplifies at least 50 target loci encompassing the cancer-specific mutations using the PCR primers, from cell-free DNA isolated from a biological sample of the subject, to obtain amplicons.
13. The method of claim 1 , wherein the multiplex targeted amplification reaction amplifies at least 100 target loci encompassing the cancer-specific mutations using the PCR primers, from cell-free DNA isolated from a biological sample of the subject, to obtain amplicons.